Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure
Top Cited Papers
Open Access
- 2 May 2007
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 297 (17) , 1883-1891
- https://doi.org/10.1001/jama.297.17.1883
Abstract
Acute decompensated heart failure (ADHF) remains a common cause of hospitalization worldwide but it is not clear how patients admitted for clinical deterioration should be managed. Patients are generally treated with diuretics and vasodilators, while patients with evidence of peripheral hypoperfusion also may receive positive inotropes, usually dobutamine or milrinone. These positive inotropic agents improve hemodynamics and symptoms by increasing intracellular cyclic adenosine monophosphate within the failing heart but have been associated with an increased risk of death and other cardiovascular events.1,2Keywords
This publication has 16 references indexed in Scilit:
- Positive Inotropic Effect of Levosimendan is Correlated to its Stereoselective Ca2+‐Sensitizing Effect but not to Stereoselective Phosphodiesterase InhibitionBasic & Clinical Pharmacology & Toxicology, 2006
- Reassessment of Dobutamine, Dopamine, and Milrinone in the Management of Acute Heart Failure SyndromesThe American Journal of Cardiology, 2005
- Demographics, Clinical Characteristics, and Outcomes of Patients Hospitalized for Decompensated Heart Failure: Observations From the IMPACT-HF RegistryJournal of Cardiac Failure, 2005
- Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)European Heart Journal, 2002
- Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trialThe Lancet, 2002
- Short-term Intravenous Milrinone for Acute Exacerbation of Chronic Heart FailureA Randomized Controlled TrialJAMA, 2002
- Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failureJournal of the American College of Cardiology, 2000
- Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart FailureCirculation, 2000
- Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytesEuropean Journal of Pharmacology, 1997
- Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendanJournal of Molecular and Cellular Cardiology, 1995